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Abstract
Background: Chronic fatigue syndrome, also known as myalgic encephalomyelitis (CFS/ME), is characterized by chronic
disabling fatigue and other symptoms, which are not explained by an alternative diagnosis. Previous trials have suggested that
graded exercise therapy (GET) is an effective and safe treatment. GET itself is therapist-intensive with limited availability.
Objective: While guided self-help based on cognitive behavior therapy appears helpful to patients, Guided graded Exercise
Self-help (GES) is yet to be tested.
Methods: This pragmatic randomized controlled trial is set within 2 specialist CFS/ME services in the South of England. Adults
attending secondary care clinics with National Institute for Health and Clinical Excellence (NICE)-defined CFS/ME (N=218)
will be randomly allocated to specialist medical care (SMC) or SMC plus GES while on a waiting list for therapist-delivered
rehabilitation. GES will consist of a structured booklet describing a 6-step graded exercise program, supported by up to 4
face-to-face/telephone/Skype™ consultations with a GES-trained physiotherapist (no more than 90 minutes in total) over 8 weeks.
The primary outcomes at 12-weeks after randomization will be physical function (SF-36 physical functioning subscale) and
fatigue (Chalder Fatigue Questionnaire). Secondary outcomes will include healthcare costs, adverse outcomes, and self-rated
global impression change scores. We will follow up all participants until 1 year after randomization. We will also undertake
qualitative interviews of a sample of participants who received GES, looking at perceptions and experiences of those who improved
and worsened.
Results: The project was funded in 2011 and enrolment was completed in December 2014, with follow-up completed in March
2016. Data analysis is currently underway and the first results are expected to be submitted soon.
Conclusions: This study will indicate whether adding GES to SMC will benefit patients who often spend many months waiting
for rehabilitative therapy with little or no improvement being made during that time. The study will indicate whether this type of
guided self-management is cost-effective and safe. If this trial shows GES to be acceptable, safe, and comparatively effective,
the GES booklet could be made available on the Internet as a practitioner and therapist resource for clinics to recommend, with
the caveat that patients also be supported with guidance from a trained physiotherapist. The pragmatic approach in this trial means
that GES findings will be generalizable to usual National Health Service (NHS) practice.
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Introduction
Background
Chronic fatigue syndrome, also known as myalgic
encephalomyelitis (CFS/ME), is a condition characterized by
chronic disabling fatigue, which is not better explained by an
alternative diagnosis [1-3]. The prevalence of CFS/ME in the
population is between 0.4 and 2.5% [3-5]. A working group,
reporting to the Chief Medical Officer for England, concluded
the following: "CFS/ME is a relatively common clinical
condition, which can cause profound, often prolonged, illness
and disability, and can have a substantial impact on the
individual and the family" [4]. The prognosis is poor with a
median of 7% recovering without treatment [6].
The National Institute for Health and Clinical Excellence (NICE)
guidelines recommend that patients with CFS/ME are offered
GET (or cognitive behavior therapy [CBT]) [7]. In support of
this guidance, two systematic reviews showed no harm to
patients from GET [8,9]; however, it was concluded that larger
trials should be completed to confirm the recommendations.
The PACE trial (pacing, graded activity, and cognitive behavior
therapy: a randomized evaluation) is the largest ever trial testing
GET and CBT for CFS with 641 secondary care patients
recruited [10]. Specialist medical care (SMC) alone was
compared with SMC plus one of three therapies (adaptive pacing
therapy, CBT, or GET). GET was found to be an effective and
safe treatment, with 82% being satisfied with GET [11]. In
contrast to this research, surveys of ME charity members have
suggested that GET is perceived as a harmful and unacceptable
treatment. In a recent survey, 56% of those who had received
GET reported feeling “worse” afterwards, with 53% reporting
GET to be unacceptable [12]. Specialist therapist-delivered GET
is also intensive and expensive, with up to 15 sessions required
over a 3 to 6-month period [9,11], and United Kingdom (UK)
National Health Service (NHS) access is often poor and with
long waiting lists [13]. An effective and safe guided self-help
GET approach would be helpful to all involved.
Self-help approaches can benefit patients with chronic fatigue
in the community [14]. In one study, fatigued patients attending
their GP were given an educational CBT self-help booklet [15],
complemented by 15 minutes of advice from a research nurse.
After 3 months, patients who received the booklet were
significantly less fatigued than the usual care group. This booklet
has since been used in another primary care trial in which
fatigued patients were offered 6 sessions of therapy with a
trained GET or CBT therapist at their GP surgery or given the
booklet without guidance as an alternative to usual care [16].
A third of patients receiving the booklet significantly improved
compared to half receiving the face-to-face therapies.
However, these two studies recruited patients from primary
care, and thus included those with less disabling fatigue than
that found in secondary care patients. In another study, a guided
CBT self-help treatment was tested in secondary care patients
with CFS/ME [17]. In this trial, significant decreases in both
fatigue and disability were observed in the guided self-help
group compared to the waiting list control. A clinically
significant improvement in fatigue (27% versus 7% of waiting
list patients) and 6-point difference in mean SF-36 physical
functioning subscale scores between groups at follow-up
resulted. However, problems with respect to engagement and
acceptability of psychotherapeutic approaches such as CBT for
patients with CFS/ME have been reported [4].
Self-management techniques have consistently been shown to
result in substantial improvements in patients with a range of
mental illnesses [18-21] and physical illnesses [22,23]. A US
study showed that patients with CFS/ME seemed to prefer
self-management approaches, particularly social support services
[24]. However, no study has investigated guided GET self-help
for CFS/ME. In the UK, patients report difficulties accessing
specialist services either because there is no local service,
because of long waits for referral and/or subsequent treatment,
or because they are too ill to travel to the clinic [25].
Approximately 40% reported waiting 6 months to see a
specialist. Thus, effective guided self-help could open up a more
accessible treatment option for many CFS patients and might
make face-to-face therapy either unnecessary, or reduce the
need for a full course of therapy.
Rationale and Piloting
Physiotherapists trained to deliver GET within the PACE trial
developed and tested the GES guide. It was developed so that
diagnosed patients attending clinics could help themselves using
such an approach with advice from their specialist clinician and
therapist. The booklet was extensively piloted by secondary
care CFS/ME patients and reviewed by several specialists in
CFS/ME and a professor of physiotherapy. This led to significant
revisions, and review, before “translation” of the guide into lay
language by a professional editor.
Hypotheses
First, we will test the null hypothesis that GES plus specialist
medical care (SMC) will be no more effective at improving
either physical disability or fatigue than usual SMC alone, as
shown by no statistically significant difference between the two
arms of the trial 12 weeks after randomization. Second, we will
test the hypothesis that GES will be acceptable to patients
diagnosed as having CFS/ME in specialist secondary care
clinics, as demonstrated by less than 25% of eligible patients
declining participation in the trial, and more than 75% of those
participating being satisfied with the approach. Third, we will
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assess the difference in the number of participants suffering
serious adverse effects, serious adverse reactions, or a serious
deterioration across the study arms.
We will also assess whether there is a statistically significant
difference in cost-effectiveness between the two interventions,
although this is not a hypothesis.
Methods
Study Design
This is a pragmatic [26] randomized controlled trial of
outpatients attending two specialist CFS/ME secondary clinics
who have been diagnosed by a specialist doctor as having
CFS/ME and referred for practitioner-delivered therapy. All
participants will be on a waiting list for therapist-delivered
treatment. Standard medical care (SMC) will be compared with
SMC plus GES.
Participants
Adults aged 18 and over will be recruited after assessment at
two CFS/ME specialist clinics in the United Kingdom (UK):
one at St Bartholomew’s Hospital (East London Foundation
NHS Trust) and the other in Kent (Kent and Medway NHS and
Social Care Partnership Trust). These services each provide
assessment and/or treatment for approximately 125 new adults
each year, referred mainly from general practitioners. Adults
are given a diagnosis after a clinical assessment, with a physical
and mental state examination, and screening blood tests
according to the guidelines produced by the National Institute
for Health and Care Excellence [7]. Approximately 57% of
adults referred to specialist CFS services have CFS/ME [27]
based on one of three possible criteria [1,2,7]; however, they
must meet NICE criteria to be entered into this trial. We chose
the NICE criteria to maximize generalizability of the trial to a
more representative sample of UK secondary care attendees, as
they are more inclusive (requiring a shorter duration and fewer
symptoms).
Inclusion/Exclusion Criteria
Patients will be included if they meet NICE criteria for CFS/ME
[7]. To meet these criteria, patients must have clinically
evaluated, unexplained, persistent or relapsing chronic fatigue
of more than 4 months with a definite onset. Their fatigue needs
to have resulted in a substantial reduction in activity, be
characterized by postexertional fatigue or malaise and be
accompanied by at least 1 of 10 possible symptoms (eg,
headaches, muscle and/or joint pain, difficulty sleeping, and
concentration problems). Patients meeting these criteria will be
referred for treatment in the service as usual and will be asked
if they would be willing to be contacted about possible
participation in the trial. Patients will not be offered trial
participation if they do not speak and read English adequately,
have current suicidal thoughts or comorbid psychiatric
conditions requiring exclusion, have read the GES guide
previously, have had previous GET therapy at one of the trial
clinics, or have physical contraindications to exercise.
Recruitment
Potentially eligible patients identified by the clinician in the
initial assessment will be informed about the study and given
an information sheet. The clinician will obtain consent from the
patient to be contacted by a researcher. If the patient is willing,
the researcher will contact the patient and arrange to meet at
the clinic or via a Skype™ telephone appointment to provide
and discuss further information about the study.
The recruiting researcher will explain the rationale for the study
and its design, uncertainties about the effectiveness of the
intervention, options available outside of the trial, and the right
not to take part in the study or to withdraw at any time up to the
analysis. Those willing to take part in the study will be asked
to consent to randomization and sign the consent form. If
informed consent is subsequently provided, the patient will
partake in an assessment. Consent to have guidance sessions
recorded will not be required to be included in the trial.
Randomization
The recruiting researcher will log in to the Web-based automated
randomization service/system operated by the UK Clinical
Research Collaboration (UKCRC) registered King’s Clinical
Trials Unit at the Institute of Psychiatry, King’s College London
for the intervention allocation, which will be conveyed to the
participant by the recruiting researcher. Allocation will be at
the level of the individual, using block randomization with
randomly varying block sizes, to preserve allocation
concealment. Randomization will be stratified by (1) depression
(Hospital Anxiety and Depression Scale; cut-off = 11); (2)
severity of disability (SF-36 physical functioning subscale ≤40
and ≥45, which was close to the mean score from all participants
in the PACE trial [11]; and (3) by center. This will help to ensure
equal proportions of depressed and more severely disabled
participants in each treatment arm. Automatic emails will
confirm the intervention allocation. If for any reason the
randomization service is unobtainable, randomization will be
completed during the next working day and the participant will
be told of the result by telephone.
Interventions
Standard Medical Care (SMC)
Participants will be informed at the end of their assessment
appointment that they have been allocated to SMC and that they
should follow the advice of their GP and specialist doctor as
usual. They will not have access to the self-help booklet used
in the trial. As per usual, specialist doctors will prescribe or
advise regarding medication as indicated for symptomatic
treatment of associated symptoms (eg, insomnia and pain) and
comorbid conditions (eg, depressive illness). These patients will
start the therapy to which they have been referred after the
endpoint of the trial at 12 weeks or more after randomization,
when it becomes available. After completion of trial
participation, these patients will also receive a copy of the GES
booklet.
SMC Plus GES
In addition to receiving SMC, participants in the GES arm will
be given a copy of a self-help booklet describing a 6-step
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program of graded exercise that should take approximately 12
weeks to complete. A physiotherapist will then join the
participant for a 30-minute appointment either face-to-face in
the clinic or via telephone/Skype™ within 5 working days of
randomization. The physiotherapist will explain how the booklet
should be used, explain steps 1 to 4 of the booklet, and answer
any questions/concerns of participants. The physiotherapist will
provide up to 3 further 20-minute telephone or Skype™ support
appointments over the next 8 weeks. These 3 follow-up
appointments will take place approximately 1 to 2, 4 to 5, and
7 to 8 weeks after the participant’s initial appointment. The
physiotherapists will be trained and experienced in delivering
GET as a treatment for CFS/ME, and in how to guide and
support participants in their use of the booklet without providing
additional therapy. The emphasis of guidance/support will be
on solutions provided by the booklet and how to apply what is
learned, and will follow a support guidance checklist. Contacts
with the physiotherapist will be audio-recorded, with informed
consent, for training and supervision purposes to ensure that
therapists adhere to the guided self-help manual. The GES
supervisor will listen to a random sample of the recordings
throughout to ensure therapists are maintaining a consistent
approach.
The Guided graded Exercise Self-help (GES) booklet is based
on the approach of GET developed for the PACE trial [11],
which was itself based on effective approaches tested in previous
trials [9]. GES is also based upon the recommendations made
by NICE in 2007 [7]. Patients with CFS/ME attending clinics
at St Bartholomew’s and King’s College hospitals in London
piloted the booklet. Engaging and encouraging participants to
undertake their exercise plans using the GES booklet are
cornerstones of the guidance and will be its main focus.
The physiotherapist will use established techniques [28] to
maximize engagement and adherence throughout. Participants
will be encouraged to approach their graded exercise program
using the 6 steps described in the booklet: stabilizing a routine,
starting regular stretching, deciding on a goal and choosing a
type of physical activity (PA), setting their PA baseline,
increasing the duration of PA, and finally increasing the intensity
of PA. During each session, the therapist will inquire about
progress and answer any questions, with a focus on moving
forward to the next step. They will recognize achievements and
provide feedback to participants on their efforts, with the aim
of increasing motivation and self-efficacy. Near the end of the
guidance intervention, the physiotherapist will discuss setbacks.
If a participant cannot be contacted by telephone or Skype™,
an email will be sent in an attempt to reengage them. After the
last guidance session, the physiotherapist will rate the
participant’s CGI (health), their adherence to the GES guided
support, and their acceptance of the therapy model.
Departure from Intended Treatment
To measure departure from intended treatment, participants will
be asked at follow-up whether they adhered to the booklet and
guidance, and how much PA they undertook in the past week.
The number of participants who actively withdraw from either
intervention will be recorded. The GES booklet is currently
only available from specialist doctors and physiotherapists at
specific CFS/ME clinics. For the duration of the trial, the GES
booklet will not be available on our websites or patient libraries.
Participants who are offered face-to-face therapy before
completion of their 12 weeks in the trial, due to an appointment
becoming available earlier than expected in the service, will
complete their follow-up measures prior to that appointment.
This will be considered a “protocol deviation.”
Assessments and Procedures
Criteria for CFS
The research assessment will include evaluation of the
operational criteria for the Oxford and Centers for Disease
Control and Prevention (CDC) criteria for CFS. Although not
eligibility criteria, these will be used in subgroup analyses [1,2].
To determine both excluding and allowable comorbid psychiatric
diagnoses, a standardized psychiatric interview (Structured
Clinical Interview for DSM-IV Axis I Disorders; SCID) [29]
will be conducted by a trained and supervised research assessor.
Baseline
The following self-rated inventories will be collected at the first
assessment (baseline): 11-item Chalder fatigue questionnaire
(CFQ), using Likert scoring [30]; SF-36 physical function short
form subscale (SF-36 PF) [31]; Hospital Anxiety and Depression
Scale (HADS) [32]; Euroqol Questionnaire (EQ-5D) [33]; Work
and Social Adjustment Scale (WSAS) [34]; International
Physical Activity Questionnaire (IPAQ) [35]; Tampa Scale of
Kinesiophobia-Fatigue (TSK-F) [36]; Client Service Receipt
Inventory (CSRI) [37]; and Patient Health Questionnaire
(PHQ-15) [38]. Participants will be asked when their CFS/ME
started; whether they have ever received GET, CBT, or pacing
from a therapist; whether they have ever used any listed self-help
resources; and whether they are members of a CFS/ME self-help
group. Participants will also be asked about their ethnicity,
highest education level, current employment status, whether
they have had to reduce/stop work due to their CFS/ME, other
health problems, and whether they are taking antidepressant
medication for any reason.
12-Weeks Post-randomization
The main outcome end-point will be 12 weeks after
randomization, before patients begin their service therapy. We
chose 12 weeks as this was about the length of the waiting list
for therapy at the St Bartholomew’s CFS service at the time of
application for funding. At the end-point, the following
information will be collected via questionnaires sent by mail
with a stamped addressed envelope: SF-36 PF, CFQ, self-rated
Clinical Global Impression of Change (CGI) [39] (this will be
done once for overall health and then a second time specifically
for CFS), HADS, EQ-5D, WSAS, IPAQ, CSRI, and PHQ-15.
Participants will be asked to describe the following: whether
they have used any of 4 listed self-help resources since
randomization, including the unpublished GES guide [40-42];
how satisfied they are with the help they received; how closely
they followed the GES guide; their current employment status
and whether they have had to reduce/stop work due to their
CFS/ME; any new health problems not already reported; and
whether they are taking antidepressant medication for any
reason.
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12-Months Post-randomization
The primary purpose of the 12-month follow-up will be to obtain
the health-economic assessment (see section below); however,
we will also collect data on the primary outcome measures and
the CGI so that we can assess longer-term physical functioning,
fatigue, and change in overall health and CFS. The following
information will be collected via questionnaires sent in the mail
with a stamped addressed envelope for return: CFQ, SF-36 PF,
CGI, EQ-5D, and CSRI.
Primary Outcomes
We initially planned to use the SF-36 PF as the primary outcome
analyzed as an interval variable collected at 12-weeks
postrandomization. The SF-36 PF is scored as the sum of
responses to 10 items related to functioning on everyday
activities from getting dressed to performing physical activities,
each of which is coded 0 for “Yes, limited a lot,” 5 for “Yes,
limited a little” and 10 for “No, not limited at all”. This yields
a score ranging from 100 for the highest level of perceived
physical functioning to 0 for being unable to bathe or dress
oneself. The SF-36 PF was to be the sole primary outcome as
we were primarily interested in change in physical function.
However, during recruitment we noticed that a significant
minority of participants scored close to the mean of the general
population (ie, normal physical function) so could be considered
recovered even before any intervention [43]. This is because
they had substantial reductions in functioning in other domains,
such as mental or social activity levels [7].
We therefore added a second primary outcome, the CFQ, which
is scored as the sum of responses to 11 items related to physical
and mental fatigue, each of which is coded 0 for less than usual,”
1 for “no more than usual,” 2 for “more than usual” and 3 for
“much more than usual,” where usual is how they felt the last
time they were feeling well. This gives us a symptomatic
measure of fatigue. The two primary outcome variables are valid
and reliable and have been used in previous CFS trials [9,11].
The ethics committee, Research and Development (R & D), and
the trial steering and data monitoring committees approved this
change (in June 2013) before any outcome data were formally
examined. Because of the change from one to two primary
outcomes, we reanalyzed our power calculation and plan to
recruit more participants (see section on sample size).
The main secondary outcome measure will be the validated
self-rated CGI score, which we will use to measure both change
in “CFS” and change in “general health” at the end of treatment,
compared with baseline. Each will have 7 possible scores from
"very much worse" (score of 7) to "very much better" (score of
1)[39]. Both safety and efficacy can be recorded with this item;
we will count scores of 1 and 2 (“very much” and “much” better)
as positive outcomes, and scores of 6 and 7 (“very much” and
“much” worse) as negative outcomes. Scores of 3-5 (“a little”
better, no change, and “a little” worse) will be regarded as no
change.
Safety Measures and Reporting
For safety outcomes, we will include serious adverse events
(SAEs), serious adverse reactions to trial treatments (SARs),
and serious deteriorations (SDs). SAEs will be defined according
to usual clinical trial definitions (ie, an event that is fatal,
life-threatening, or results in or prolongs hospitalization; an
increase in severe and persistent disability or incapacity;
self-harm; or any other important condition that may require
medical or surgical intervention to prevent the above [10] and
will be reported to the appropriate authorities in the standard
manner. SARs are SAEs that are considered to be a reaction to
any trial therapy or drug prescribed. SDs will be defined as any
of the following outcomes: CGI scores of 6 and 7, active
withdrawal from the intervention due to worsening, or a
reduction on the SF-36 PF scale by 10 or more points.
Participants will record any nonserious adverse events (NSAEs)
in their follow-up questionnaire. An adverse event is defined
as any clinical change, disease, or disorder recorded by the
participant, whether or not it is considered to be related to the
trial or its treatments. Participants will be asked to record
whether they believe the adverse event was “related to following
the GET guide.” In the event of an adverse event (AE), the
center leader will judge the seriousness of the event, and, if
judged to be serious, the relationship to a trial supplementary
therapy or SMC prescribed treatment, and the expectedness of
the event. The trial manager will report all SAEs to the principal
investigator (PI) within 24 hours, regardless of the relationship
to trial treatment. Reporting of SAEs and SARs will be carried
out according to normal regulatory research governance
requirements.
After an SAE or SAR, the center leader will make a decision
as to whether the participant should be withdrawn from either
randomized treatment or from the trial, or if an alteration in
their SMC is needed; arrangements will be made for further
assessment and management as required. The trial manager will
provide the center leader with monthly follow-up reports until
resolution. These reports will be communicated to the Data
Monitoring and Ethics Committee (DMEC), and other
appropriate authorities via the trial manager.
A risk assessment has been undertaken and we have concluded
that the therapies are of low risk to participants. NSAEs will be
reported en bloc to the DMEC on a regular basis, according to
the usual regulatory requirements.
Measures Used for Economic Evaluation
Quality of life and function will be measured using the EQ-5D
and the WSAS. The EQ-5D will also be used to generate
quality-adjusted life years (QALYs) and linked to costs
measured using data collected with the CSRI. The IPAQ will
determine PA participation before and after the intervention,
and the TSK-F will determine beliefs about exercise at baseline.
Participants will be asked about their current employment status
and whether they have had to reduce/stop work due to their
CFS/ME. The physiotherapist will record the number of contacts
and the length of each contact, and during the final guidance
session, will measure adherence to the GES guided support.
Other service use during the trial will be reported by participants
completing the CSRI at follow-up, including use of primary
and secondary care services, use of other self-help approaches
such as the Internet, books or voluntary sector support,
medication, therapy outside of the trial, complementary
JMIR Res Protoc 2016 | vol. 5 | iss. 2 | e70 | p.5http://www.researchprotocols.org/2016/2/e70/
(page number not for citation purposes)
Clark et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
healthcare, and care from family/friends. By accessing clinic
notes and relevant electronic databases, we will also collect data
on how many therapy sessions participants went on to receive
after their trial participation up to one year after randomization.
Non-Responders
If a returned form is incomplete, the researcher will contact the
patient, usually by telephone, to acquire any missing data. In
the event that no outcome data is completed or returned after 2
telephone attempts spaced 1 week apart, the researcher will
email or text the participant to ask for answers over the
telephone or via email solely for the 2 primary outcomes and
the CGI. The researcher will make a file note that the outcome
data were collected in this way. If a participant withdraws from
the treatment, but not the trial, data will be collected in the usual
way. If the participant is not willing to provide all follow-up
data, a request will be made to complete only the primary
outcome and CGI; if the participant agrees, these will be
completed immediately.
Statistical Considerations
Blinding to Outcome Measures
The members of the Trial Steering Committee (TSC), the
DMEC, and the trial statistician will be blinded to treatment
allocation. The trial manager (TM) and physiotherapists will
not be blind to allocation, as they will inform participants of
their allocation and deliver the intervention. To further minimize
observer bias, outcomes will be self-rated by the participant,
and outcome assessments will be coordinated by the TM. The
trial statistician will be masked to treatment group until after
the main analysis is completed.
Sample Size
Our original sample size was based upon the SF-36 PF as our
primary outcome; however, the significance level was reduced
to 2.5% to accommodate 2 primary outcomes [31]. A large
previous trial of CFS/ME using the SF-36 PF (the PACE trial)
indicated a baseline mean score of 37 (SD 15) and an outcome
score of 48 (SD 21) following 12 weeks of practitioner-led GET,
an 11-point increase [11]. Based on these previous findings,
and our estimate that GES will be less effective than GET, the
sample size calculations are based on the assumption that a
mean difference of 8 (SD 18) points between intervention arms
at the 12-week follow-up will be a clinically useful difference
on the SF-36 PF scale after 12 weeks [11]. Thus, assuming a
significance level (alpha) of 2.5% and power of 80%, we require
a minimum of 98 participants in each group. This sample size
will be upwardly adjusted to allow for loss to follow-up and
other compliance issues. Based upon previous trials, we expect
about 10% loss to trial follow-up [17]; therefore, we will recruit
109 patients in each group (a total of 218).
Based on a previous trial of GET, in which the difference
between baseline and 12 weeks was 5.4 points on the CFQ [11],
we assume that a mean difference of 3 (SD 6) points will
represent a clinically useful difference at the 12-week follow-up.
Hence, assuming a significance level (alpha) of 2.5% and power
of 80%, we require a total of 174 patients, which is less than
the 218 to be recruited, so adequate power will be achieved.
Data Entry and Analysis
Data will be double entered by a dedicated data-entry researcher.
The analysis and presentation of the trial will be in accordance
with CONSORT guidelines including a flow diagram of
enrollment, allocation, follow-up, and analysis [26,44]. We plan
to use descriptive statistics to compare characteristics of invited
individuals who did or did not agree to take part and eligible
individuals who were randomized or not randomized (pending
ethical approval). We will also examine differences between
trial arms in important baseline participant characteristics.
Descriptive Statistics for Primary and Secondary
Outcomes
Box plots will be used to assess the data distribution of
continuous measures. Descriptive statistics will be broken down
by intervention group at baseline and follow-up. Normality of
the scales and regression residuals will be explored using
diagnostic plots, and if the assumption of normality is violated,
the data will be transformed. We will present means and
standard deviations for all normally distributed measures, and
medians and quartiles for nonnormal measures. Discrete
outcomes will be described using both number and percentage.
Missing Data
Item-level missing data on the primary and secondary outcome
variables at baseline and follow-up will be imputed using mean
replacement (prorating). Prorating will be implemented only
when less than 20% of item responses per scale are missing.
The reasons for missing baseline and follow-up whole-scale
data will be summarized using the CONSORT diagram. We
will identify baseline characteristics associated with missing
data to allow us to impute data to do sensitivity analyses.
Analysis for Hypothesis 1
Our primary intention-to-treat analysis will compare the SF-36
PF and CFQ at 12 weeks between groups adjusted using
multivariable linear regression analyses [45]. Intention-to-treat
(ITT) analyses will be conducted on data from all randomized
participants with information at follow-up (ie, modified ITT)
regardless of any departure from the allocated treatment arm.
We will adjust for our stratification factors (depression, center,
and severity of disability) as well as baseline values of outcomes
and treatment arm.
A secondary analysis will explore the association between
treatment arm and having achieved a clinically useful
improvement on the SF-36 PF (ie, an 8-point increase) and the
CFQ (ie, a 3-point decrease) using chi-squared analysis.
Analysis of the secondary outcome, the CGI, will compare the
proportions scoring “much” or “very much” better (1 and 2),
the proportions scoring “a little better,” “no change,” or “a little
worse” (3 to 5), and the proportions scoring “much” or “very
much” worse (6 and 7) across treatment arms, using an ordinal
logistic regression adjusting for our stratification variables.
Sensitivity Analysis
Sensitivity analysis will be conducted to assess the impact of
missing data on our results. We will estimate whole-scale
missing data due to loss to follow-up using multiple imputation
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by chained equation. This will allow us to conduct a strict ITT
for all respondents who took part at baseline. Following recent
guidelines, we will also conduct a sensitivity analysis that will
take into account the partially nested design of the study and,
therefore, assess the potential impact of the “therapist effect”
on our results [46]. Further analysis will be conducted to adjust
for potential confounders, including sex and age.
A per-protocol analysis will serve as a further sensitivity analysis
to investigate the robustness of the conclusions of the primary
analysis, following departures from the randomized intervention
policies. This will exclude those participants in the control arm
who used a GET self-help approach. Subgroup analyses
including only those meeting the Oxford or CDC criteria for
CFS will also be undertaken. We will analyze moderators of
improvement, such as these criteria, but also depression and
severity of physical function and fatigue. These subgroup
analyses are exploratory and will be interpreted with due caution
[47].
Analysis for Hypotheses 2 and 3
Chi square will be used to describe any difference in satisfaction
(ie, satisfied vs nonsatisfied) across treatment arms and any
differences in SAEs, SARs, or serious deterioration (1+ vs none)
across treatment arms.
The above plan is what we intend to do; however, the final
analyses reported may differ from those planned, allowing for
post hoc analysis where it is indicated [48]. We will report
alternative methods if statistical models do not converge, and
omit planned analyses that are superseded, redundant, or no
longer of interest. We will report any changes in consequent
papers.
Economic Evaluation
The economic analysis will take a health and social care
perspective. Service use will be combined with appropriate unit
costs (eg, from Kent University and NHS Reference Costs) to
generate service costs. QALYs gained over the period from
baseline to 12-week follow-up will be generated using
area-under-the-curve methods from the EQ-5D (using published
tariffs from the University of York) combined with costs in the
cost-effectiveness analysis. If the intervention group has lower
costs and better outcomes than the control group, then the
intervention will be seen as “dominant.” If the intervention
group has higher costs and better outcomes, we will use
incremental cost-effectiveness ratios to identify the extra cost
incurred to achieve one extra QALY. Uncertainty around
cost-effectiveness estimates will be explored using
cost-effectiveness planes (produced from outcome-cost
combinations from 1000 bootstrapped resamples). Interpretation
will be aided using cost-effectiveness acceptability curves
derived using the net-benefit approach with values between £0
and £100,000, placed on a QALY gain so as to include the
threshold used by NICE (2007) [7]. We will also conduct similar
analyses using costs and the primary outcome measure.
However, QALYs are the main measure for the economic
evaluation given that thresholds for cost-effectiveness used by
NICE exist.
12-Week Follow-Up
The main outcomes, including QALYs, will be measured over
the 12-week period from baseline assessment to follow-up. We
would expect to see a change in the EQ-5D (which provides us
with QALY information) and the WSAS over this time. We
will also measure the intervention costs and any short-term
impact on the use of other services through the CSRI. We
recognize that longer-term impacts, which we are unable to
measure may also be important. We will measure serious
deterioration using a composite measure including the CGI
(“much” or “very much worse”), those who actively withdraw
from their intervention, or those whose SF-36 PF score falls by
10 or more points.
12-Month Follow-Up
We will go on to measure how many appointments each
participant has with an SMC doctor and with a therapist (and
which therapist: psychologist, physiotherapist, occupational
therapist, or group therapy) after their trial participation up to
12 months from randomization. We will estimate the costs of
the interventions and compare between the groups.
Data Protection
Participants will be allocated a unique 8-digit identification
number made up of a center number, an individual patient
number, and patient initials. This number is assigned to the
patient and is used on assessment forms prior to transfer of data,
so that they are anonymized at source. A list of names and
corresponding identification numbers will be kept separately
and securely on an encrypted university server. All guided
support sessions will be audio-recorded if consent is given, and
they will be stored on an encrypted university server.
Data Monitoring
The DMEC will receive notice of SAEs and SARs for the
sample as a whole and per treatment arm. If the incidence of
SAEs of a similar type are greater than would be expected in
this population, the DMEC will be able to retrieve data
according to trial arm, to determine any evidence of excess in
either arm. NSAEs will be included in the safety reporting of
the completed trial. Suspected unexpected serious adverse
reactions (SUSARs) will be reported separately.
Independent Scrutiny
At the end of the trial, two independent scrutineers will be
appointed to consider whether any AE is an SAE and whether
any SAE is an SAR. These figures will be reported.
Compliance
The trial will be conducted in compliance with the Declaration
of Helsinki, the trial protocol, Medical Research Council Good
Clinical Practice (GCP) guidance, the Data Protection Act
(1998), the Multi-centre Research Ethics Committee (MREC),
and Local Research Ethics Committees (LREC) approvals and
other regulatory requirements, as appropriate. The final trial
publication will include all items recommended under
CONSORT [49].
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Qualitative Study
Purpose
We will undertake a nested qualitative study with a subsample
of participants to ascertain patients’ views and experiences of
GES, specifically looking for differences in perceptions and
experiences between those who improved and worsened with
GES.
Both our patient representatives and the TSC suggested using
the trial to better understand why patients vary in their responses
to graded exercise therapy (GET), particularly by examining
engagement and other barriers/facilitators to successful
treatment. The best way to gather this knowledge is to undertake
a small qualitative study, stratified by both good and poor
outcomes. We will conduct one-on-one interviews with
participants who have taken part in the active arm of the trial
to investigate variations in participant attitudes to, and
experiences of, GES. This study will be nested within the
time-frame for the main trial.
Background Issues
A recent meta-synthesis of qualitative studies uncovered various
ways in which people with CFS/ME interpret and experience
their illness and their treatments [50]. Themes included wide
variability in symptoms, amount of perceived control, and
theories about causation and best coping strategies (eg, reducing
activities, listening to the body, and balancing activities).
Perspectives of patients are also known to change with treatment
experience. For instance, if beliefs about the need to avoid
exercise and less helpful thought patterns can be addressed (eg,
catastrophic thinking), then improvements in fatigue may follow
[51]. At the same time, some patient organizations believe that
one particular treatment, graded exercise therapy (GET), is
harmful to CFS/ME patients [12]. Qualitative research can
provide a deeper understanding of the way that participants
approach, experience, and give meaning to interventions like
GES [52]. There is no published, qualitative research that
investigates variation in participant attitudes to, and experiences
of, GET in a randomized controlled trial. Yet, the evidence is
that patients who benefit from such interventions are likely to
approach the intervention differently than those who do not
[53]. Our preliminary (unpublished) analysis of free-text
feedback from GET participants in the PACE trial [11]
suggested different categories of participants. For instance,
people differed in their appraisals of GET from positive to
negative, and whether they attended more to the learning,
support, treatment, and/or contextual issues outside of the trial.
However, we do not yet have sufficient data to examine the
significance of different styles of patient engagement with GET.
Research Questions for the Qualitative Study
The following two research questions will be investigated in
the qualitative study: (1) Are there any differences in treatment
perceptions and experiences between those trial participants
who improved and those who worsened during use of guided
self-help based on GET? and (2) What are the implications for
the way patients understand “getting better?”
Recruitment and Sampling Strategy
We aim to recruit up to 20 participants, all of whom will have
received GES. Participants will be stratified into 2 similar-sized
groups of either improvement or deterioration (CGI score at
12-week follow-up assessment of “much” or “very much” better
versus “much,” or “very much” worse) for comparison [39].
We will seek written informed consent from these 20
participants. Participants will have completed the 12-week
follow-up assessment, and will be recruited at least one month
later to allow time for them to reflect on their GES and trial
experience.
Participant Involvement
Participants will undertake a one-off semistructured interview,
either face-to-face, by telephone, or by Skype™, depending on
their preference.
Data Collection
Qualitative semistructured interviews, digital audio-recorded,
with fully informed consent, will be conducted with participants.
An experienced qualitative researcher will conduct the
interviews, using a semistructured approach [54]. By ensuring
the same topics are covered in each interview, we will collect
comparable data about participants’ experiences of the trial and
treatment within each group. In addition, the semistructured
approach will allow greater flexibility for participants to
highlight their specific concerns, meanings, and priorities, even
if not anticipated by the researchers. Topics will include before
and after trial well-being, expectations of treatment,
understanding of “baseline” and “recovery,” the meaning of
exercise, barriers and facilitators to treatment, and any outside
influences on trial participation. Thus, we will use an approach
suited to collecting a wide range of experiences in each group.
We will use face-to-face interviews to collect people’s
experiences (eg, in people’s homes, or a university interview
room). We will also use less conventional ways to include the
perspectives of people who may have trouble participating; for
example, recording of interviews over the phone, or the use of
Skype™ video calls for interviews. Sample questions are
provided in Multimedia Appendix 1.
Data Management and Analysis
The audio-recordings from the interviews will be professionally
transcribed (a confidentiality agreement will be in place). The
transcription will be reviewed against the audio by the researcher
for errors and to remove any identifying information, and then
returned to the participant to check accuracy and add any
clarifying points at the end of the interview, with a deadline of
one month to reply.
Thematic analysis (ie, “identifying, analyzing, and reporting
patterns within data”) is a basic building block of all kinds of
qualitative analysis [55], and will be the approach used for
analysis in this study. Data will be inputted and coded in the
qualitative data analysis software environment, NVivo. NVivo
will aid the coding of themes, organization, and searching of
all interviews in both patient outcome categories (improvement
vs worsening). The software will enable the comparison of
themes across the full range of data (constant comparison, ie,
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comparing all bits of similar data with each other) [56] so more
robust conclusions can be drawn.
While the researcher will drive the analysis, all investigators
will be involved in group analytical sessions, debating and
clarifying themes, and drafting of reports to arrive at the final
analysis.
Patient and Public Involvement
Patients were significantly involved in the design and piloting
of the GES booklet before the trial started. Two patient
representatives have also advised us in design of this trial and
in the application and amendments to this trial. A patient
representative is a member of the TMC, which will meet twice
yearly. This individual will therefore be intimately involved in
all aspects of this trial, so that we can ensure that this research
reflects the needs and views of the patient group. A
representative of the Association for Young People with ME
will sit on the TSC.
Ethics and Dissemination
The study was approved on November 23, 2011 (reference
11/LO/1572) by NRES Committee London, London Bridge.
Four favorable opinions were provided on May 8, 2012, May
31, 2012, June 27, 2012, and June 20, 2013, for amendments
to the study protocol and documents. A fifth amendment,
requesting the addition of a nested qualitative study was rejected
on 2014 September 1, with the suggestion it should be submitted
as a separate study. The qualitative study received a favorable
ethical opinion on January 9, 2015 (reference 15/WM/0007) by
NRES Committee West Midlands, The Black Country. All
patients involved in the study provided informed consent to take
part in the study.
The results of the GETSET study will be disseminated to the
scientific community, media, relevant charities, and general
public. Results will be published in peer-reviewed international
journals and will be presented at national and international
conferences and symposiums.
Results
The trial has finished recruiting (first randomization: May 15,
2013; last randomization: December 24, 2014). Follow-up for
the main analysis was completed in April 2014 and long-term
follow-up in March 2016. Data analysis are underway and the
first results are expected to be submitted for publication later
this year.
Discussion
CFS/ME is a relatively common and frequently disabling
condition with limited treatment options of proved efficacy
available within the NHS. GET is recommended, but access to
it is limited, with patients often spending many months waiting
for rehabilitative therapy with no help given during that time.
The longer someone has CFS/ME, the worse the prognosis [6].
Guided exercise self-help (GES) has never been tested in a
randomized controlled trial for CFS/ME. It is important for
people with CFS and the NHS to know whether GES is more
effective, and cost-effective, when used with SMC, than when
SMC is used alone.
If this trial shows GES to be acceptable and safe, and shows a
clinically useful difference between arms, then the GES booklet
will be made available on the Internet and through other media
as a practitioner resource, with the knowledge that it is an
acceptable, safe, and effective treatment when supported by
advice from a trained therapist. If found to be cost-effective,
then it could be recommended for commissioners of services.
It could be used as a first line of treatment while patients are
waiting for face-to-face specialist practitioner-delivered
therapies, such as GET and CBT. Guided self-help exercise
could become the first step in a stepped-care approach for
CFS/ME in the NHS, by training current physiotherapists to
deliver it.
The next trial would be to test this intervention in primary care,
which could immediately follow this trial. The secondary care
trial is necessary first, to ensure this intervention is effective in
those with properly diagnosed CFS/ME, before testing it in
those at the primary care level, where the diagnosis is not so
well-established [57].
If shown to be an effective treatment, this policy of providing
a guided self-help approach to initially stabilize and then
increase PA in patients with CFS/ME could also be tested for
patients with many other chronic disabling conditions known
to respond to practitioner-delivered graded exercise approaches,
including arthritis, chronic obstructive airways disease, and
diabetes mellitus [58].
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